ProCE Banner Activity

Phase II CodeBreaK100: Overall Survival and Exploratory Subgroup Analyses of Sotorasib in Pretreated KRAS p.G12C–Mutated NSCLC

Slideset Download
Conference Coverage
Clinical benefit of sotorasib in patients with previously treated KRAS p.G12C–mutated NSCLC observed across subgroups prespecified by baseline characteristics and in exploratory analyses of molecularly defined subgroups.

Released: June 07, 2021

Expiration: June 06, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme